Aduro names Gerald Chan to board
This article was originally published in Scrip
Aduro BioTech, a clinical-stage biotechnology company, has named Dr Gerald Chan to its board of directors. Dr Chan is the co-founder of Morningside, a private investment group with venture, private equity and property investments. He currently serves on the boards of Advanced Cell Diagnostics, Oxyrane, Stealth Peptides, Synchroneuron, Apellis, Nucana, VTI and Matrivax. Furthermore, Dr Chan is a member of the Global Advisory Council of the International Society for Stem Cell Research, the Global Advisory Council of Harvard University, the Dean's Board of Advisors of the Harvard School of Public Health and the advisory boards of the Cold Spring Harbor Conferences Asia, the Johns Hopkins Nanjing Center, and the Columbia University Center for Radiological Research.